secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001171843-25-002987
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M
---------------------------------------------------------------------------

- Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.
- Net loss $10.7M ($0.36/share) vs $6.6M ($0.27/share) a year ago.
- Operating expenses $13.0M, up from $8.7M on commercial expansion and R&D.
- Cash $46.4M at March 31; 30,053,142 shares outstanding as of May 8.
- Urology APC Level 7 codes effective 2025; TULSA-AI BPH module and TULSA+ planned H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325002987/0001171843-25-002987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325002987/f8k_050825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer